Ghent University Academic Bibliography

Your filters: cql: author="Lindberg, Johan" or (type any "bookEditor issueEditor" and editor="Lindberg, Johan")

Add to list
- Journal Article
- A1
- open access
AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Jan Vanwelkenhuyzen (UGent) , Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost (UGent) , et al.

(2023) EUROPEAN UROLOGY OPEN SCIENCE. 53. p.63-66
Add to list
- Conference Paper
- C3
Toward methodology for comprehensive androgen receptor splice variant profiling in cell-free RNA from patients with metastatic prostate cancer

Jan Vanwelkenhuyzen (UGent) , Pieter-Jan van Dam, Katleen De Preter (UGent) , Johan Lindberg, Piet Ost (UGent) and Bram De Laere (UGent)

(2022) Belgian Association for Cancer Research, 2022 Annual meeting, Abstracts.
Add to list
- Conference Paper
- C3
Towards the discovery of prognostic and predictive biomarkers in CHEERS, a radioimmunotherapy phase II trial

Jan Vanwelkenhuyzen (UGent) , Mathieu Spaas (UGent) , Kim Van der Eecken, Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Lieve Brochez (UGent) , Johan Lindberg, Katleen De Preter (UGent) , Bram De Laere (UGent) and Piet Ost (UGent)

(2022) OncoPoint Symposium, 8th, Abstracts.
Add to list
- Conference Paper
- C3
Inferring the genomic landscape of lymph-node positive high-risk prostate cancer

Jan Vanwelkenhuyzen (UGent) , Kim Van der Eecken, Bram De Laere (UGent) , Simon Sundling, Rebecka Bergström, Johan Lindberg, Katleen De Preter (UGent) , Henrik Grönberg and Piet Ost (UGent)

(2020) 7th edition of the annual BMUC meeting, Abstracts.
Add to list
- Journal Article
- A1
- open access
The ProBio trial : molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Alessio Crippa, Bram De Laere (UGent) , Andrea Discacciati, Berit Larsson, Jason T. Connor, Erin E. Gabriel, Camilla Thellenberg, Elin Janes, Gunilla Enblad, Anders Ullen, et al.

(2020) TRIALS. 21(1).
Add to list
- Journal Article
- A1
- open access
Has the PROPHECY of AR-V7 been fulfilled?

Bram De Laere, Piet Ost (UGent) , Henrik Gronberg and Johan Lindberg

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(24). p.2181-2182
Add to list
- Journal Article
- A1
- open access
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, et al.

(2019) CLINICAL CANCER RESEARCH. 25(6). p.1766-1773
Add to list
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Bram De Laere, Prabhakar Rajan, Henrik Gronberg, Luc Dirix, Johan Lindberg, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, et al.

(2019) JAMA ONCOLOGY. 5(7). p.1060-1062
Add to list
- Journal Article
- A1
- open access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost (UGent) , Wim Demey, Lucien Hoekx, Dirk Schrijvers, et al.

(2018) GENOME MEDICINE. 10.

Academic Bibliography

AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer

Toward methodology for comprehensive androgen receptor splice variant profiling in cell-free RNA from patients with metastatic prostate cancer

Towards the discovery of prognostic and predictive biomarkers in CHEERS, a radioimmunotherapy phase II trial

Inferring the genomic landscape of lymph-node positive high-risk prostate cancer

The ProBio trial : molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

Has the PROPHECY of AR-V7 been fulfilled?

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer

Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Contents

Support

Contact